CPHI:NYE-China Pharma Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.2099

Change

+0.00 (+0.43)%

Market Cap

USD 3.69M

Volume

2.51M

Analyst Target

USD 3.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.92 (-0.56%)

USD 74.37B
HLN Haleon plc

-0.10 (-1.03%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

+0.13 (+0.99%)

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.29 (+1.86%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

+0.01 (+0.08%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.03 (-0.38%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.04 (+0.53%)

USD 2.75B
YCBD cbdMD Inc

+0.02 (+4.43%)

USD 1.96M
EBS Emergent Biosolutions Inc

-0.15 (-1.78%)

N/A

ETFs Containing CPHI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -65.02% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.02% 7% C- 2% F
Trailing 12 Months  
Capital Gain -65.02% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.02% 7% C- 2% F
Trailing 5 Years  
Capital Gain -98.27% 14% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.27% 14% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 22.50% 87% B+ 83% B
Dividend Return 22.50% 87% B+ 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 365.86% 13% F 3% F
Risk Adjusted Return 6.15% 40% F 24% F
Market Capitalization 3.69M 20% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector